Live feed22:15:00·265dPRReleasevia QuantisnowNew Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS ObservedByQuantisnow·Wall Street's wire, on your screen.TEVA· Teva Pharmaceutical Industries LimitedHealth Care